Clinical trial · Interventional
Personalized Therapy of Precursor Lymphoid Neoplasms
Optimization of the Treatment of Adults With Precursor Lymphoid Neoplasms With Adjustment of the Type and Intensity of the Therapy for Age, Status of Minimal Residual Disease, Genetic and Phenotypic Features
NCT01665001CI-TRIAL-00007843unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary goal of this study by The Polish Adult Leukemia Group (PALG) is to verify if individual therapeutic approach taking into account biological and phenotypic differences as well as response at the level of minimal residual disease is associated with improved outcome of adults with precursor lymphoid neoplasms
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Precursor Lymphoid Neoplasms | Precursor Lymphoid Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Treatment strategy: induction, consolidation, HSCT, maintenance | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Multiagent induction-consolidation
- description
- Induction, consolidation, HSCT, maintenance for adults with newly diagnosed precursor lymphoid neoplasms
- interventionNames
- Other: Treatment strategy: induction, consolidation, HSCT, maintenance
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- three years
Secondary outcomes (1)
- measure
- Leukemia-free survival
- timeFrame
- three years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * New diagnosis of PLN according to WHO 2008 classification * Age ≥18 years * Biological status allowing administration of induction therapy * Informed patient consent form signed Exclusion Criteria: * Pregnancy * Psychiatric diseases * History of other malignancies * HIV infection * Active hepatitis * Hypersensitivity to drugs used in induction
References
Publications (1)
- BACKGROUNDHolowiecki J, Krawczyk-Kulis M, Giebel S, Jagoda K, Stella-Holowiecka B, Piatkowska-Jakubas B, Paluszewska M, Seferynska I, Lewandowski K, Kielbinski M, Czyz A, Balana-Nowak A, Krol M, Skotnicki AB, Jedrzejczak WW, Warzocha K, Lange A, Hellmann A. Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study. Br J Haematol. 2008 Jun;142(2):227-37. doi: 10.1111/j.1365-2141.2008.07185.x. Epub 2008 May 19. PMID 18492099